James leads commercial interactions for DATA-CAN, the HDR UK hub for cancer data, working with patients, data controllers, data scientists and companies to increase the research use of UK cancer data. James has been at the forefront of genetics and data in the UK for ten years, since setting up Cancer Research UK’s Stratified Medicine Programme with AstraZeneca and Pfizer, and the parallel Stratified Medicine Innovation Platform with the Technology Strategy Board. He subsequently was a founding partner of Syncona, the Wellcome Trust’s venture capital arm, focussed on UK genetic and data opportunities. He joined Genomics England as first employee and Managing Director of the Main Programme, setting up the sequencing and sample acquisition operations of this national initiative with Illumina and the NHS Genomics Medicine Centres. He then worked in the Precision Medicine and Medicines Discovery Catapults, helping UK SMEs with access to samples and data. Since founding Precision Strategy James has worked with major UK clients including HDR UK, ABPI, Sensyne Health, Roche, Novartis and a number of start-up companies.
James served on the Human Genomic Strategy Group and the Emerging Science and Bioethics Advisory Committee.